Pfizer Boosts Forecast for Vaccine Sales to $33.5 Billion
- Surging demand pushes shot to top tier of drug blockbusters
- Drugmaker plans delta booster trial; also flu, RSV, Lyme shots
Vials of the Pfizer-BioNTech Covid-19 vaccine at a vaccination site in South Korea.
Photographer: SeongJoon Cho/BloombergThis article is for subscribers only.
Pfizer Inc. now expects its Covid-19 vaccine to bring in $33.5 billion in revenue this year, putting it on course to become one of the best-selling medicines of all time.
The New York drugmaker had previously projected vaccine sales for the year of $26 billion. The upward revision is a sign demand for the shots, which Pfizer sells with German partner BioNTech SE, is surging as countries battle new outbreaks fueled by the delta virus variant.